# NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer

Source: https://onco.cc/trials/nct06459869/  
OnCo record `nct06459869` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of NG-350A run by Akamis Bio, active, not recruiting.

## Summary

NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer is a phase 1 interventional study registered as NCT06459869 by Akamis Bio, with 33 participants planned, started 2025-04-07, primary completion expected 2027-01-30. Conditions recorded: Locally Advanced Rectal Cancer (LARC). Interventions recorded: NG-350A IV administration, Capecitabine oral administration, Radiotherapy.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06459869
- Phase: 1
- Setting: A Multicentre, Open-label, Non-randomized, Phase 1b Trial of NG-350A, a Tumour-selective Anti-CD40-expressing Adenoviral Vector, in Combination With Chemoradiotherapy in Locally Advanced Rectal Cancer (FORTRESS)
- Sponsor: Akamis Bio
- Enrolled: 33

## Sources

- ClinicalTrials.gov NCT06459869: https://clinicaltrials.gov/study/NCT06459869

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- drugs: [NG-350A](https://onco.cc/drugs/ng-350a/)
- companies: [Akamis Bio](https://onco.cc/companies/akamis-bio/)

---
JSON: https://onco.cc/api/v1/entities/nct06459869.json